Last updated on July 2019

A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer


Brief description of study

A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer

Detailed Study Description

The purpose of this study is find out what effects, both good and bad, an experimental drug called entinostat has on you and your cancer, when given together with the standard hormonal drug treatment, exemestane. Exemestane is an aromatase inhibitor (drugs that lower estrogen) which is used in breast cancer patients to inhibit the growth of the breast cancer. In this study, you will take exemestane, and either entinostat or an inactive substance (placebo). Entinostat is investigational and has not been approved by the Food and Drug Administration (FDA) for use in this cancer. If you are male, you will also receive Goserelin, a luteinizing hormone releasing hormone (LHRH) agonist that is used to suppress the production of testosterone and estrogen.

Clinical Study Identifier: TX140449

Find a site near you

Start Over